W ithin the last decade, transcatheter aortic valve implantation (TAVI) has become a well-established treatment for severe aortic stenosis in patients deemed noneligible for surgical aortic valve replacement. 1, 2 In surgical prosthetic valves, previous reports have demonstrated that thrombosis is associated with significant morbidity and mortality. [3] [4] [5] [6] [7] The information on transcatheter heart valve (THV) thrombosis with regard to frequency, mechanisms, and clinical significance is sparse and based on sporadic case reports. [8] [9] [10] [11] [12] [13] [14] 
See Editorial by Mylotte and Piazza
Prosthetic valve thrombosis is defined as any thrombus not caused by infection and that is attached to or near a surgical valve resulting in some degree of blood flow obstruction, interference with valve function, or is sufficiently large to warrant treatment. 15 Clinically, this condition may be obstructive or nonobstructive. Patients with obstructive prosthetic valve thrombosis most often present with congestive heart failure, whereas patients with nonobstructive prosthetic valve thrombosis typically are asymptomatic. Moreover, patients with left-sided prosthetic valve thrombosis are at increased risk of stroke. 6, 7 In addition to the risk of thromboembolism, prosthetic valve thrombosis may lead to valve dysfunction and reduced valve durability. 16 Echocardiography has been the key diagnostic tool in evaluating the presence of prosthetic valve thrombosis. 16 A significant increase in the transvalvular pressure gradient with correspondingly decreasing valve area as revealed by transthoracic echocardiography (TTE) is suggestive of prosthetic valve dysfunction; however, the identification of prosthetic valvular thrombus is difficult with TTE. 17 Transesophageal echocardiography (TOE) is currently the test of choice for the diagnosis of prosthetic valve thrombosis because of better visualization of both the function of the prosthetic valve Background-Early stent valve thrombosis after transcatheter aortic valve implantation (TAVI) is a rare complication, which is diagnosed based on the appearance of clinical symptoms of heart failure and echocardiographic findings. After TAVI, transthoracic echocardiography is performed to assess transcatheter heart valve (THV) function. However, preliminary reports indicate the potential additive clinical value of multidetector computed tomography (MDCT) for the diagnosis of THV thrombosis. We sought to determine the value of MDCT for the diagnosis of THV thrombosis and the frequency of this complication after balloon-expandable TAVI. Methods and Results-MDCT was performed in 140 patients within 1 to 3 months after TAVI with the Edwards Sapien XT THV to assess the presence of THV thrombosis and THV stent geometry. Post-TAVI MDCT identified THV thrombosis in 5 patients (4%). Of note, 4 of these patients were asymptomatic and had a normal transthoracic echocardiographic examination without signs of thrombus formation or flow obstruction. In patients with THV thrombosis, a left ventricular ejection fraction of <35% was present in 3 (60%), whereas 2 (40%) did not receive standard post-TAVI dual-antiplatelet therapy. Neither THV underexpansion nor THV noncircularity was detected in patients with THV thrombosis. Conclusions-Post-TAVI MDCT is a valuable tool for the diagnosis of THV thrombosis, and this complication seems to be more common than previously anticipated. Larger studies are required to identify specific risk factors of THV thrombosis. (Circ Cardiovasc Interv. 2015;8:e001596. DOI: 10.1161/CIRCINTERVENTIONS.114.001596.) THV Thrombosis Detected by MDCT leaflets and echo dense structures adherent to the prosthetic heart valve. 16, 17 Preliminary reports indicate the potential additive clinical value of multidetector computed tomography (MDCT) to standard care for the diagnosis of prosthetic valve (including THV) thrombosis. 8, 9, 18, 19 Given the limitations of routine TTE thrombosis surveillance of postimplant THVs, we sought to determine the incidence of THV thrombus on post-TAVI MDCT and to determine potential causative factors using a multimodality imaging strategy comprising TTE, TOE, and MDCT.
Methods

Study Population
From August 2011 to November 2013, 168 patients underwent TAVI at Aarhus University Hospital, Denmark. Of these, 140 patients had MDCT performed 1 to 3 months post-TAVI according to the institutional standard clinical protocol to evaluate THV positioning and geometry, as well as the presence of THV thrombosis or contained aortic root injury. These 140 patients formed the basis of the present study. In the remaining 28 patients, post-TAVI MDCT was not performed because of death before follow-up (n=12), severely impaired renal function (n=2) or patient refusal to follow-up (n=14).
Follow-up clinical and echocardiographic data were obtained from subsequent visits in our outpatient clinic. In all patients, the balloonexpandable Edwards Sapien XT THV (Edwards Lifesciences, Irvine, CA) was implanted, either via the transapical, transfemoral or transaortic approach, as previously described. 20 The selection of THV size (23 mm, 26 mm, or 29 mm) was based on pre-TAVI MDCT measurements of the mean aortic annular diameter and area as previously described. 21 Balloon underfilling was performed in selected cases. 22 In patients with severely depressed left ventricular ejection fraction (LVEF, <25%), TAVI was performed on cardiopulmonary support. This study was approved by The Danish Data Protection Agency and The Danish National Board of Health. All procedures were performed as part of standard clinical care, and therefore, informed patient consent was not required.
Echocardiographic Assessment
All patients underwent routine TTE before TAVI to assess LVEF and aortic valve stenosis severity (mean/peak gradient in mm Hg and area in cm 2 ), and at predischarge for assessment of THV function. At 1 to 3-month follow-up, TTE and TOE were performed to evaluate THV function. THV gradients and regurgitation were evaluated by color and continuous-wave Doppler. Leaflet mobility and thickness were analyzed from multiple 2-dimensional (2D) views. Changes in cusp thickness and mobility, and the presence and characteristics of valvular masses, were assessed from both TTE and TOE images. In patients with THV thrombosis, TTE and TOE were repeated 3 months later to evaluate thrombus status and THV function. All echocardiographic examinations were performed by experienced cardiologists using a Philips iE33 (Philips Healthcare, Best, The Netherlands) or a GE Vivid E9 (General Electric Vingmed, Horten, Norway) echocardiography system.
MDCT Scan Protocol
Pre-and post-TAVI contrast-enhanced MDCT examinations were performed in the caudocranial direction using a second-generation dual-source CT system (Siemens Somatom Definition Flash; Siemens Healthcare, Erlangen, Germany). Pre-TAVI MDCT scans were performed using a retrospectively ECG-gated helical acquisition in 131 (94%) patients and a low-dose contrast prospectively ECG-triggered high-pitch helical acquisition in 9 patients with mildly impaired renal function. Post-TAVI MDCT scans were performed
WHAT IS KNOWN
• The diagnosis of prosthetic valve thrombosis by echocardiography can be challenging.
• To date, only sporadic case reports have been published on transcatheter heart valve thrombosis.
WHAT THE STUDY ADDS
• This is the first report on transcatheter heart valve thrombosis evaluation in a consecutive cohort of patients.
• The incidence of transcatheter heart valve thrombosis may be higher than previously expected.
• As a supplment to standard transthoracic and transesophageal echocardiography, postprocedural computed tomography is a valuable tool for transcatheter heart valve thrombosis detection. THV redilatation, n (%) 8 (6) CPS, n (%) 10 (7) THV size, n (%) Nominal THV oversizing relative to annulus area (%) 17.6±12.1 THV balloon underfilling, n (%) 25 (18) Data are presented as mean±SD, n (%) or median (interquartile range). AV indicates aortic valve; BMI, body mass index; CPS, cardiopulmonary support; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MDCT, multidetector computed tomography; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; and THV, transcatheter heart valve. using a prospectively ECG-gated sequential acquisition in all patients. Commercially available contrast media (Optiray 350 mg/mL) was used (20 mL for the test bolus and 70 mL for all scans, except for the prospectively ECG-triggered high-pitch helical scan in which 40 mL of contrast was applied). Contrast injection was followed by a 50 mL saline flush. Heart rate (HR) reduction with β-blockade was not performed. MDCT was performed with a collimation of 128×0.625 mm, z-flying spot, a gantry rotation time of 280 ms, and the scan pitch was 0.20 to 0.40 for retrospective scans (depending on the HR) and 3.4 for prospective high-pitch helical scans. Maximum tube current ranged from 450 to 750 mA with a fixed tube potential of 100 (body mass index, <30 kg/m 2 ) or 120 kV (body mass index, >30 kg/m 2 ). To reduce radiation in retrospective scans, ECG-controlled tube current modulation was applied with reduction of the current to 20% of maximum. In the event of a HR of >75 bpm, full current was applied from 25% to 45% of the RR-interval, HR 65 to 75 bpm: full current between 30% and 70%, and HR <65 bpm: full current between 65% and 75%, respectively. Acquisition for functional analysis was not applied.
MDCT Analysis
MDCT examinations were analyzed using commercially available software (SyngoVia and Multimodality Workplace; Siemens Healthcare, Erlangen, Germany). Aortic annular dimensions were assessed in double-oblique transverse reconstruction of the aortic annular plane as previously described. 23 On post-TAVI MDCTs, the leaflets of the valve were evaluated for signs of thrombosis defined as a low-attenuating mass attached to THV cusps or diffuse thickening of ≥1 THV cusps identifiable in both double-oblique axial and multiplanar reformatted reconstructions. CT attenuation values of the low-attenuating masses and the intraventricular septum were measured using a region of interest of 0.1 cm 2 . 24 Image quality for evaluation of cusp anatomy was deemed insufficient if the contours of all 3 cusps were not clearly delineated. THV position was deemed too high when the inflow of the THV was above the basal insertion of the native aortic leaflets and too low when the outflow portion of the sealing cuff (lower two thirds) of the THV was below the most basal insertion of the native aortic leaflets as identified and defined on pre-TAVI MDCT. 23 Post-deployment THV dimensions (outer stent frame area and short-and long-axis diameter) were evaluated at 3 levels: inflow, midportion, and outflow. THV eccentricity was determined as 1−(minimum THV diameter/maximum THV diameter). The THV was deemed noncircular if eccentricity was >10% at all 3 levels. THV expansion was defined as THV area MDCT /THV area nominal . THV underexpansion was defined as an expansion ratio of ≤90% at all 3 levels. 25 
Statistical Analysis
Demographic and clinical patient-related data were obtained from Aarhus University Hospital, Skejby medical records. The distribution of continuous variables was tested for normality by QQ-plots and histograms. Continuous parametric variables are presented as mean±SD, and continuous nonparametric variables are presented as median (interquartile range). Categorical variables are presented as frequencies (percentages).
Results
Baseline clinical, echocardiographic, MDCT, and procedural characteristics for the total study population are shown in Table 1 .
Post-TAVI MDCT
The median (interquartile range) interval between the TAVI procedure and MDCT follow-up in the THV thrombosis group was 91 (66-92) days versus 92 (72-119) days in the THV control group. Image quality of the post-TAVI MDCT was insufficient for assessment of cusp anatomy in 39 (28%) of the 140 patients because of the presence of ≥1 compromising artifacts Noncircular THV †, n (%) 0
Data are presented as mean±SD. TAVI indicates transcatheter aortic valve implantation; and THV transcatheter heart valve.
*THV underexpansion was defined as an expansion ratio of ≤90% at all 3 levels.
†THV was deemed noncircular if eccentricity was >10% at all 3 levels. THV Thrombosis Detected by MDCT (severe blooming, n=30; motion, n=21; low contrast opacification, n=14; breathing artifacts, n=20). In 5 (4%) patients, post-TAVI MDCT identified THV thrombosis observed as low-attenuation masses attached to THV cusps and was clearly distinctive from the leaflet tissue itself (Figure) . All thrombus masses were located on the aortic side of the cusps. Mean±SD (range) CT attenuation values of the THV thrombi were 92±48 HU (29-157 HU) as compared to 83±20 HU (64-106 HU) in the intraventricular septum.
In 2 (1%) patients, post-TAVI MDCT depicted a discretely thickened THV cusp with no low-attenuating mass and no abnormal findings on TTE and TOE. Further follow-up in these patients demonstrated unchanged echocardiographic and MDCT examinations; thus, these 2 patients were deemed not to have THV thrombosis.
Thrombus formation in the left atrial appendage was detected in 1 patient with THV thrombosis. Contained aortic root injury was observed in 1 patient in the control group. Underexpanded THVs were detected in 10 (7%) patients, none of whom experienced THV thrombosis (Table 2) . THV geometry was circular in all patients. The THV was malpositioned (too high or low) in 1 (17%) patient in the THV thrombosis group versus 9 (7%) in the control group.
Patients With THV Thrombosis
As mentioned above, THV thrombosis was detected in a total of 5 patients (Table 3) . Of these, THV thrombosis was detected on routine follow-up in 4 asymptomatic patients (patient No. 1-4; Table 3 ). Predischarge TTE revealed normal findings on anatomy and transvalvular flow in these patients. At followup, the transvalvular gradient had increased slightly in patient No. 3 (peak gradient from 13-29 mm Hg and mean gradient from 8-15 mm Hg), but a stable effective orifice area of 1.3 to 1.4 cm 2 confirmed normal THV function. Gradients remained unchanged in the 3 other asymptomatic patients. TOE demonstrated restrictive movement of ≥1 cusps in all these patients (Movie I in the Data Supplement), whereas clearly mobile masses were identified in patient No. 2 (Table 4) . One or more low-attenuated masses attached to cusps and cusp thickening were identified by MDCT in all patients (Table 4; Figure) . Patient No. 5 was admitted to hospital before planned followup visit (day 44 after TAVI) because of severe decompensated heart failure. TTE demonstrated a depressed LVEF of 30%, a trans-THV peak gradient of 21 mm Hg, an effective orifice area of 0.6 cm 2 , and a Doppler velocity index of 0.20, thereby indicating significant THV stenosis (Table 3) . No anatomic structures suggestive of THV thrombosis were depicted on CHF indicates congestive heart failure; LC THV , THV cusp located in the native left coronary cusp position; LMWH, low-molecular weight heparin; MDCT, multidetector computed tomography; NC THV , THV cusp located in the native noncoronary cusp position; RC THV , THV cusp located in the native right coronary cusp position; s.c., subcutaneous; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve; TOE, transesophageal echocardiography; and UFH, unfractionated heparin.
*Time (d) between transcatheter aortic valve implantation and the THV thrombosis diagnosis. EOA indicates effective orifice area; LVEF, left ventricular ejection fraction; N/A, not applicable; TAVI, transcatheter aortic valve implantation; and THV, transcatheter heart valve. THV Thrombosis Detected by MDCT TTE. TOE revealed restrictive movement of 2 cusps, and MDCT identified cusp thickening and low-attenuated masses corresponding to these cusps (Table 4) .
Among patients with THV thrombosis, an LVEF of <35% was present in 3 (60%), atrial fibrillation in 1 (20%), and moderate/severe mitral regurgitation in 3 (60%) patients (Table 3) . Patient No. 3 in the THV thrombosis group was known to have idiopathic thrombocytopenic purpura, whereas none of the other patients in the THV thrombosis group had a history of venous thrombosis or coagulation disorders.
No embolic events were recorded, and there were no clinical or biochemical evidence of endocarditis in any of the 5 patients.
Antithrombotic/Anticoagulation Therapy
At the time of the THV thrombosis diagnosis, 3 patients were taking standard dual-antiplatelet medication, whereas 2 patients received single-antiplatelet therapy (aspirin or clopidogrel alone; Table 5 ). In 3 patients with THV thrombosis, anticoagulation therapy (target international normalized ratio of 2.0-3.0) in combination with either aspirin or clopidogrel was initiated after the diagnosis of THV thrombus. The patient with idiopathic thrombocytopenic purpura was treated with subcutaneous low-molecular weight heparin instead of warfarin (Table 4 ). The patient with obstructive THV thrombosis and severe congestive heart failure was treated with unfractionated heparin infusion followed by low-molecular weight heparin and warfarin but developed refractory heart failure and died on day 137 post-TAVI. No autopsy was performed.
After 3 months on warfarin or low-molecular weight heparin treatment, 4 of the patients were still asymptomatic, and a new TOE and MDCT examination showed full resolution of thrombus ( Figure) and normalized cusp mobility (Movie II in the Data Supplement).
Discussion
In this observational study, the reported incidence of THV thrombosis after TAVI with the balloon-expandable Edwards THV was higher than expected. Although the majority of the patients were asymptomatic, the finding of THV thrombosis is of clinical importance because it identifies a potentially reversible cause of THV dysfunction and a substrate for thromboembolism. Thus, early diagnosis and treatment may prevent future thromboembolic events and development of THV stenosis.
Importantly, our data raise the question as to whether THV thrombus formation previously has been underdiagnosed. In addition, because follow-up TTE was without anatomic signs of thrombus formation in all cases and with significant THV stenosis in only 1 of 5 cases, the value of TTE in diagnosing THV thrombus seems limited. Even TOE with its improved definition of the THV valve structure and function may be of limited value for the diagnosis of THV thrombosis because of acoustic shadowing, making demarcation of the thrombus from the prosthetic valve difficult. 26 Based on the findings in this study, contrast MDCT with its 3D information and high spatial and contrast resolution seems to provide the necessary image detail to detect thrombus in a fashion superior to TOE.
In the majority of previously reported cases of THV thrombosis, patients presented with symptoms of heart failure because of THV stenosis (Table 6) . [10] [11] [12] [13] [14] Notably, in several of these cases, THV thrombus was not directly visible on TOE. Moreover, THV thrombosis was diagnosed by routine post-TAVI MDCT in 1 case only. 11 The diagnosis of prosthetic valve thrombosis is challenging for many reasons. For one, it is often mistaken for primary prosthetic valve degeneration. Although in our cases, the diagnosis of THV thrombosis was not confirmed by histology or autopsy, several findings supported the conclusion of THV thrombus formation. THV thrombosis and dysfunction were rapidly reversible by anticoagulation as documented by follow-up TOE and MDCT showing complete resolution of the initial findings in 4 of 5 patients. Moreover, the timing (1-3-month post-TAVI) and the absence of leaflet calcification are unusual for THV degeneration. Furthermore, the location of our findings is unusual for pannus, as only the prosthetic valve leaflets were involved with sparing of the bare struts on the ventricular side. 24 Data on the value of measuring CT attenuation values for distinguishing prosthetic valve thrombosis from pannus formation are sparse and equivocal. 24, 27, 28 To date, the largest study with direct comparison of MDCT findings and surgery (n=9) demonstrated higher mean CT attenuation values of pannus when compared with the intraventricular septum. 24 Although the generalizability of these previous data is uncertain because CT attenuation values vary between different scanners and convolution kernels, our findings of similar CT attenuation values of the THV cusp masses when compared with the intraventricular septum further strengthen that these masses represent thrombi rather than pannus. 29 Predisposing factors to THV thrombosis may theoretically involve hemostatic factors (eg, inadequate antithrombotic treatment and concurrent prothrombotic conditions), hemodynamic factors (eg, low flow circumstances because of depressed LVEF and localized regions of turbulent flow because of THV underexpansion/noncircularity), and endothelial factors (eg, delayed endothelialization of the metallic THV frame). 16 Although THV underexpansion/noncircularity and THV frame-thrombus interaction involvement was not observed in this study, an LVEF of <35% was present in 3 Data are presented as n(%). TAVI indicates transcatheter aortic valve implantation; and THV, transcatheter heart valve.
(60%) patients, and 2 (40%) patients did not receive standard post-TAVI dual-antiplatelet therapy. However, larger studies are needed to further characterize specific risk factors of THV thrombosis.
The frequency of incidental THV thrombosis calls into question the adequacy of current antithrombotic/anticoagulation strategies. In this institution, standard post-TAVI antithrombotic treatment comprises dual-antiplatelet therapy with aspirin (75 mg/day) and clopidogrel (75 mg/day) for the first 12 months followed by lifelong aspirin (75 mg/day). This strategy is based on the guidelines on dual-antiplatelet therapy after percutaneous coronary intervention with stenting, assuming that the rates of acute or subacute thrombosis secondary to the thrombogenicity of metal stent struts are comparable.
30
Anticoagulation therapy is prescribed in the event of atrial fibrillation. In this study, we observed THV thrombosis in 2 patients with severely depressed LVEF despite sufficient dualantiplatelet therapy. As such, the findings in this study indicate that anticoagulation may be indicated 3-6 months post-TAVI in certain high-risk patients. Further studies are needed to determine the optimal individualized antithrombotic/anticoagulation regime after TAVI.
Study Limitations
Although this study identifies MDCT as a valuable tool for THV thrombus detection, image quality was not sufficient to evaluate cusp anatomy in 28% of cases. The incidence of thrombosis on the balloon-expandable THV in this observational survey may not be generalizable to other types of THVs and patient cohorts. This is the largest series of consecutive THV thrombosis cases yet reported, and our results provide insight on the follow-up strategy and anticoagulation treatment in TAVI patients. However, the small sample size in this study did not allow for statistical testing of the association between clinical and procedural factors and the risk of THV thrombosis; thus, further investigation in larger studies are warranted. CHF indicates congestive heart failure; LVEF, left ventricular ejection fraction; MDCT, multidetector computed tomography; N/A, not applicable; NYHA, New York Heart Association; TEE, transesophageal echocardiography; THV, transcatheter heart valve; and TOE, transesophageal echocardiography.
*Time (months) between transcatheter aortic valve implantation and the THV thrombosis diagnosis. THV Thrombosis Detected by MDCT Hypothetically, a reduced antiplatelet effect of aspirin or clopidogrel in certain patients could have implications for the risk of THV thrombosis; however, the association with aspirin or clopidogrel nonresponder state was not assessed in the present study. Administration of contrast may be problematic in TAVI patients whom often have impaired renal function. However, the use of low (≈40 mL) contrast dose protocols in certain subsets of patients may be sufficient for post-TAVI MDCT assessment. 31 The introduction of new CT modalities and optimizing scan protocols may allow for reduction of radiation dose. 31 Although our patients with nonobstructive THV thrombosis responded successfully to anticoagulant therapy, the long-term THV and clinical outcome are still unknown and longer follow-up series with imaging are required.
Conclusions
THV thrombosis after balloon-expandable TAVI seems to be more common than previously anticipated and is commonly occult on TTE. The role of routine postprocedural MDCT as a supplement to routine TTE and TOE for detection of THV thrombosis in patients potentially at a heightened risk of thrombus formation needs further investigation. Larger studies are required to identify specific risk factors of THV thrombosis.
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